Economic evaluations in rheumatoid arthritis
How this Evidence Map was generated
We searched heoro.com on 26th October 2022 for economic evaluations of drug treatments to treat rheumatoid arthritis. This updated an earlier search conducted in 2018.
Relevant abstracts have been indexed to the following fields:
- Disease - the stage of disease or line of treatment.
- Interventions - the interventions assessed in each study.
- Study type - the type of economic model reported by each study: cost-effectiveness, cost-utility or cost-benefit, or systematic reviews of such publications.
- Locations - the geographical location of the study.
In addition the following publication date segmentations are used:
1960 to 1999, 2000 to 2004, 2005 to 2009, 2010 to 2014, 2015 to 2019, 2020 onwards
We searched the heoro.com database on 26th October 2022 using the following strategy:
Disease: Arthritis, Rheumatoid
Study type: Economic model studies: Cost-benefit study OR Cost-effectiveness study OR Cost-utility study
This retrieved 276 articles, of which 153 reported details of a cost-benefit, cost-effectiveness or cost-utility assessment for a pharmaceutical or biological therapy to treat the manifestations of rheumatoid arthritis, and were indexed in this Evidence Map.
More guidance on how to use the Evidence Mapper is here.
A poster summarising the earlier Evidence Map from 2018 can be downloaded from the Resources page.
